238 related articles for article (PubMed ID: 31076930)
1. In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection-D1 Versus D2 Versus D3?
Mogal H; Fields R; Maithel SK; Votanopoulos K
Ann Surg Oncol; 2019 Sep; 26(9):2912-2932. PubMed ID: 31076930
[TBL] [Abstract][Full Text] [Related]
2. Lymph node dissection in resectable advanced gastric cancer.
de Steur WO; Dikken JL; Hartgrink HH
Dig Surg; 2013; 30(2):96-103. PubMed ID: 23867585
[TBL] [Abstract][Full Text] [Related]
3. Extent of lymph node dissection for adenocarcinoma of the stomach.
Mocellin S; McCulloch P; Kazi H; Gama-Rodrigues JJ; Yuan Y; Nitti D
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD001964. PubMed ID: 26267122
[TBL] [Abstract][Full Text] [Related]
4. Gastric cancer: Current status of lymph node dissection.
Degiuli M; De Manzoni G; Di Leo A; D'Ugo D; Galasso E; Marrelli D; Petrioli R; Polom K; Roviello F; Santullo F; Morino M
World J Gastroenterol; 2016 Mar; 22(10):2875-93. PubMed ID: 26973384
[TBL] [Abstract][Full Text] [Related]
5. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer.
McCulloch P; Niita ME; Kazi H; Gama-Rodrigues JJ
Br J Surg; 2005 Jan; 92(1):5-13. PubMed ID: 15635680
[TBL] [Abstract][Full Text] [Related]
6. Resection for gastric cancer in the community.
van de Velde CJ
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S90-3. PubMed ID: 16399441
[TBL] [Abstract][Full Text] [Related]
7. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.
Cuschieri A; Weeden S; Fielding J; Bancewicz J; Craven J; Joypaul V; Sydes M; Fayers P
Br J Cancer; 1999 Mar; 79(9-10):1522-30. PubMed ID: 10188901
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial.
Shen J; Cao B; Wang Y; Xiao A; Qin J; Wu J; Yan Q; Hu Y; Yang C; Cao Z; Hu J; Yin P; Xie D; Gong J
Trials; 2018 Aug; 19(1):432. PubMed ID: 30092843
[TBL] [Abstract][Full Text] [Related]
9. [Total gastrectomy for gastric cancer: can the type of lymphadenectomy condition the long-term results?].
Di Martino N; Izzo G; Cosenza A; Vicenzo L; Monaco L; Torelli F; Basciotti A; Brillantino A; Marra A
Suppl Tumori; 2005; 4(3):S84-5. PubMed ID: 16437920
[TBL] [Abstract][Full Text] [Related]
10. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach.
McCulloch P; Nita ME; Kazi H; Gama-Rodrigues J
Cochrane Database Syst Rev; 2003; (4):CD001964. PubMed ID: 14583942
[TBL] [Abstract][Full Text] [Related]
11. WITHDRAWN: Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach.
McCulloch P; Nita ME; Kazi H; Gama-Rodrigues JJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD001964. PubMed ID: 22258947
[TBL] [Abstract][Full Text] [Related]
12. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.
Hartgrink HH; van de Velde CJ; Putter H; Bonenkamp JJ; Klein Kranenbarg E; Songun I; Welvaart K; van Krieken JH; Meijer S; Plukker JT; van Elk PJ; Obertop H; Gouma DJ; van Lanschot JJ; Taat CW; de Graaf PW; von Meyenfeldt MF; Tilanus H; Sasako M
J Clin Oncol; 2004 Jun; 22(11):2069-77. PubMed ID: 15082726
[TBL] [Abstract][Full Text] [Related]
13. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach.
McCulloch P; Nita ME; Kazi H; Gama-Rodrigues J
Cochrane Database Syst Rev; 2004 Oct; (4):CD001964. PubMed ID: 15495024
[TBL] [Abstract][Full Text] [Related]
14. Lymph node dissection for gastric cancer: Establishment of D2 and the current position of splenectomy in Europe and Japan.
Faiz Z; Hayashi T; Yoshikawa T
Eur J Surg Oncol; 2021 Sep; 47(9):2233-2236. PubMed ID: 33910779
[TBL] [Abstract][Full Text] [Related]
15. D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial.
Degiuli M; Reddavid R; Tomatis M; Ponti A; Morino M; Sasako M;
Eur J Cancer; 2021 Jun; 150():10-22. PubMed ID: 33887514
[TBL] [Abstract][Full Text] [Related]
16. Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials.
Mocellin S; Nitti D
Cancer Treat Rev; 2015 May; 41(5):448-54. PubMed ID: 25814393
[TBL] [Abstract][Full Text] [Related]
17. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis.
Jiang L; Yang KH; Guan QL; Zhao P; Chen Y; Tian JH
J Surg Oncol; 2013 Jun; 107(8):807-14. PubMed ID: 23512524
[TBL] [Abstract][Full Text] [Related]
18. Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer.
Hartgrink HH; van de Velde CJ
J Surg Oncol; 2005 Jun; 90(3):153-65. PubMed ID: 15895448
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
Lu W; Zeng X; Li N; Liu H
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1136-1141. PubMed ID: 30370512
[TBL] [Abstract][Full Text] [Related]
20. Prognostic benefit of extended radical lymphadenectomy for patients with gastric cancer.
Ikeguchi M; Oka S; Gomyo Y; Tsujitani S; Maeta M; Kaibara N
Anticancer Res; 2000; 20(2B):1285-9. PubMed ID: 10810436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
